Reata Pharmaceuticals, Inc.
RETA · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | $4,232 | $3,359 | $1,380 | $918 |
| - Cash | $49 | $85 | $42 | $32 |
| + Debt | $166 | $118 | $119 | $141 |
| Enterprise Value | $4,349 | $3,392 | $1,457 | $1,027 |
| Revenue | $23 | $0 | $1 | $1 |
| % Growth | 11,564.6% | -78.7% | 69.3% | – |
| Gross Profit | $22 | $0 | $1 | $1 |
| % Margin | 96.3% | 100% | 100% | 100% |
| EBITDA | $193 | -$110 | -$117 | -$68 |
| % Margin | 849.8% | -56,495.9% | -12,825.2% | -12,604.8% |
| Net Income | $193 | -$111 | -$86 | -$77 |
| % Margin | 848.5% | -56,801% | -9,354.7% | -14,220.6% |
| EPS Diluted | 4.65 | -3 | -2.35 | -2.1 |
| % Growth | 255% | -27.7% | -11.9% | – |
| Operating Cash Flow | -$70 | -$81 | -$50 | -$47 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$70 | -$82 | -$51 | -$47 |